financial results
Bio-Rad plans to drive adoption of Stilla's all-in-one Nio+ dPCR system while also incorporating its own assays to expand the menu.
Full-year 2024 revenues were down 23 percent year over year, as the firm missed Wall Street estimates on the top and bottom lines.
The firm said that it does not expect NIH spending cuts, but its internal modeling shows the potential loss of 2025 revenues topping out at around $15 million.
Between 20 percent and 25 percent of 10x Genomics' revenues are tied to NIH-funded projects, and grant money heading 10x's way was already expected to be down.
Waters Q4 Revenues Rise 6 Percent
The company's Q4 revenues were $872.7 million versus $819.5 million in Q4 2023 and above the consensus Wall Street estimate of $856.9 million.